Herfarth, Division of Gastroenterology awarded $8.3 million NIH grant

The NIH has awarded $8.3 million to a consortium of investigators, lead by Hans Herfarth, MD, PhD, Professor of Medicine in the Division of Gastroenterology & Hepatology, for the investigation of the clinical efficacy of methotrexate in patients with active ulcerative colitis.

Herfarth, Division of Gastroenterology awarded $8.3 million NIH grant click to enlarge Hans Herfarth, MD, PhD

Kim Isaacs, MD, PhD, professor of Medicine is also one of the co-investigators. The investigators plan to conduct a randomized, double blind, prospective trial investigating the efficacy of methotrexate in induction and maintenance of steroid free remission in UC. Methotrexate has been already proven to be effective in another inflammatory condition of the gastrointestinal tract, Crohn’s disease and is as well used in patients suffering of rheumatoid arthritis or psoriasis. Dr. Herfarth and his team expect to start the clinical study in January 2012. Twenty to thirty centers in the US will participate in this large multi-center study. The results of the trial are expected in 2016.

Filed under: ,